Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach.

@article{Kumar2018PulmonaryAP,
  title={Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach.},
  author={Anupam Kumar and Basem B Abdelmalak and Yoshikazu Inoue and Daniel A. Culver},
  journal={The Lancet. Respiratory medicine},
  year={2018},
  volume={6 7},
  pages={
          554-565
        }
}

Figures from this paper

Pulmonary Alveolar Proteinosis Management: Current and Future Therapeutic Strategies
TLDR
The critical distinctions between the different forms of pulmonary alveolar proteinosis are reviewed, as well as the efficacy of current, and prospective therapies for autoimmune and hereditary pulmonaryAlveolarproteinosis.
Pulmonary Alveolar Proteinosis: A Case of Acute RespiratoryFailure and Crazy Paving
TLDR
It is highlighted the importance of considering PAP when crazy paving is observed, to facilitate the correct diagnosis early and provide the best treatment, and the improvement due to treatment with WLL.
Bronchoalveolar Lavage Findings in a Pediatric Patient With Primary Pulmonary Alveolar Proteinosis
TLDR
A 13-year-old female patient presented with a 6-month history of progressive dyspnea on exertion, with serology confirming a primary autoimmune process, and pathologic findings were consistent with the clinical suspicion of PAP.
Pulmonary alveolar proteinosis complicated with tuberculosis: A case report
TLDR
This case highlighted that diagnostic bronchoalveolar lavage in combination with anti-tuberculosis treatment is a safe and effective option for mild PAP patients with tuberculosis.
The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review
TLDR
Rec recombinant human GM-CSF products may have potential for treatment of aPAP and possibly other infectious and pulmonary diseases due to its pleotropic immunomodulatory actions.
Management of primary pulmonary alveolar proteinosis: A multicentric experience
TLDR
WLL is a safe, effective therapy in an experienced setting in patients with PAP and provides long-lasting benefits, according to a multicentric experience of management of primary PAP.
Pulmonary Alveolar Proteinosis due to Familial Myelodysplastic Syndrome with resolution after stem cell transplant
TLDR
A case of a 30-year-old female with a history of familial myelodysplastic syndrome with GATA 2 mutation who presented to the outpatient clinic with several months of progressive dyspnea and nonproductive cough is reported, confirming the diagnosis of S-PAP.
...
...

References

SHOWING 1-10 OF 119 REFERENCES
Pulmonary alveolar proteinosis: progress in the first 44 years.
TLDR
There has been rapid progress toward elucidation of the molecular mechanisms underlying both the congenital and acquired forms of pulmonary alveolar proteinosis, following serendipitous discoveries in gene-targeted mice lacking granulocyte-macrophage colony-stimulating factor.
Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis
TLDR
There are at least two congenital forms of the disease, several different animal models suggesting that pulmonary alveolar proteinosis is unlikely to be a single disease entity and more likely to represent a clinical syndrome, and the overall prognosis is good.
Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis.
TLDR
Granulocyte–macrophage colony-stimulating factor autoantibodies occur in patients with Idiopathic pulmonary alveolar proteinosis and may mediate the pathogenesis of this disease, but they are also present in healthy persons and in immune globulin prepared from plasma obtained from healthy persons.
From the archives of the AFIP: pulmonary alveolar proteinosis.
TLDR
Current research supports the theory that PAP is the result of pathophysiologic mechanisms that impair pulmonary surfactant homeostasis and lung immune function, and new therapies directed toward the identified defect in immune defense have met with moderate clinical success.
An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis.
TLDR
In this series of 25 patients, the largest reported to date, administration of GM-CSF improved oxygenation as assessed by a 10 mm Hg decrease in alveolar-arterial oxygen gradient, as well as improvement in other clinical and quality of life parameters, indicate that subcutaneous GM- CSF therapy is a promising alternative to WLL for symptomatic patients with PAP.
Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis.
TLDR
The concept that adult idiopathic PAP is an autoimmune disease defined by the presence of anti-GM-CSF is confirmed and strengthened and may be used as an indicator of pulmonary alveolar proteinosis to avoid the use of more invasive means of evaluating patients with pulmonary disease characterized byAlveolar infiltrates.
Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis
TLDR
The patient was treated with an anti-CD20 antibody rituximab which resulted in dramatic improvement and her saturation during rest with high-flow oxygen treatment was 85% and she no longer required supplemental oxygen.
A Plasmapheresis Protocol for Refractory Pulmonary Alveolar Proteinosis
TLDR
It is suggested that five consecutive days of plasmapharesis results in increased clearance of anti-GM-CSF and may be potentially efficacious in cases of refractory PAP.
...
...